Antiverse has successfully identified functional antibody clusters targeting two G-protein-coupled receptors (GPCRs), both displaying versatile binding profiles and nanomolar affinity. The company has raised $3 million in funding, which will enable in-house development of the antibodies showing the highest affinity blocking function. The antibodies were identified using Antiverse’s proprietary computational antibody drug discovery platform, which […]
Menu ≡ ╳ 
